Marja-Riitta Taskinen

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk
   2019/08/31 by François Mach, Alberico L Catapano, Alberico L. Catapano +142 · 18 citations
   Economics, Econometrics and Finance · Medicine · #Diabetes, Cardiovascular Risks, and Lipoproteins #Health Systems, Economic Evaluations, Quality of Life #Lipoproteins and Cardiovascular Health
2. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
   2020/01/08 by Jan Borén, M John Chapman, M. John Chapman +48 · 1 voice · 9 citations
   Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · Medicine · #Atherosclerosis and Cardiovascular Diseases #Cancer, Lipids, and Metabolism #Lipoproteins and Cardiovascular Health
3. New insights into the pathophysiology of dyslipidemia in type 2 diabetes
   2015/02/07 by Marja‐Riitta Taskinen, Marja-Riitta Taskinen, Jan Borén · 28 citations
   Medicine · Biochemistry, Genetics and Molecular Biology · #Diabetes, Cardiovascular Risks, and Lipoproteins #Lipid metabolism and disorders #Cancer, Lipids, and Metabolism
4. Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society
   2021/09/02 by Henry N Ginsberg, Chris J Packard, M John Chapman +19 · 1 citation